The beginning of the end of warfarin?

Eikelboom, John W; Hankey, Graeme J

doi:10.5694/j.1326-5377.2004.tb06088.x

Topics

Randomised trials suggest that ximelagatran is “non-inferior” to warfarin for preventing stroke in patients with non-valvular atrial fibrillation, but important questions remain

Royal Perth Hospital, Perth, WA.

Correspondence:

Competing interests:

Graeme Hankey is a member of the Steering Committee of the AMADEUS trial, the Stroke Advisory Committee of the ACTIVE trial, and the Atrial Fibrillation Advisory Board for Exanta, AstraZeneca, Australia.

1. Hart RG, Halperin JL, Pearce LA, et al. Lessons from the Stroke Prevention in Atrial Fibrillation Trials. Ann Intern Med 2003; 138: 831-838.
2. Lake FR, Cullen KJ, de Klerk NH, et al. Atrial fibrillation and mortality in an elderly population. Aust N Z J Med 1989; 19: 321-326.
3. Thrift AG, Dewey HM, Macdonell RAL, et al. Incidence of the major stroke subtypes: initial findings from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2001; 32: 1732-1738.
4. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501.
5. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119 (1 Suppl); 8S-21S.
6. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomised trials translate into clinical practice? JAMA 2003; 290: 2685-2692.
7. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality. N Engl J Med 2003; 349: 1019-1026.
8. SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor Ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 1691-1698.
9. The Executive Steering Committee on behalf of the SPORTIF V investigators. Stroke prevention using the oral direct thrombin inhibitor Ximelagatran in patients with nonvalvular atrial fibrillation (SPORTIF V). Late-breaking clinical trial abstracts [abstract]. Circulation 2003; 108: 2.
10. Halperin JL. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003; 146: 431-438.

Online responses are no longer available. Please refer to our instructions for authors page for more information.